Postpartum Depression Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression
Verified date | November 2023 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 and to evaluate the safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, electrocardiogram (ECG) parameters, and the Columbia Suicide Severity Rating Scale (C-SSRS).
Status | Completed |
Enrollment | 276 |
Est. completion date | December 11, 2018 |
Est. primary completion date | November 15, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Key Inclusion Criteria: - Participant either must have ceased lactating at screening or, if still lactating or actively breastfeeding at screening, must agree to temporarily cease giving breast milk to her infant(s) - Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Axis I Disorders (SCID-I) - Participant was <=six months postpartum. Key Exclusion Criteria: - Active psychosis - Attempted suicide associated with current episode of postpartum depression - Medical history of seizures - Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder. Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria might apply. |
Country | Name | City | State |
---|---|---|---|
United States | Sage Investigational Site | Atlanta | Georgia |
United States | Sage Investigational Site | Aventura | Florida |
United States | Sage Investigational Site | Beverly Hills | California |
United States | Sage Investigational Site | Chapel Hill | North Carolina |
United States | Sage Investigational Site | Decatur | Georgia |
United States | Sage Investigational Site | Fort Worth | Texas |
United States | Sage Investigational Site | Hoffman Estates | Illinois |
United States | Sage Investigational Site | Houston | Texas |
United States | Sage Investigational Site | Lake Charles | Louisiana |
United States | Sage Investigational Site | Las Vegas | Nevada |
United States | Sage Investigational Site | Little Rock | Arkansas |
United States | Sage Investigational Site | Manhasset | New York |
United States | Sage Investigational Site | Miami | Florida |
United States | Sage Investigational Site | New Orleans | Louisiana |
United States | Sage Investigational Site | New York | New York |
United States | Sage Investigational Site | Oceanside | California |
United States | Sage Investigational Site | Orem | Utah |
United States | Sage Investigational Site | Orlando | Florida |
United States | Sage Investigational Site | Owensboro | Kentucky |
United States | Sage Investigational Site | Pensacola | Florida |
United States | Sage Investigational SIte | Pinellas Park | Florida |
United States | Sage Investigational Site | Providence | Rhode Island |
United States | Sage Investigational Site | Raleigh | North Carolina |
United States | Sage Investigational Site | Richardson | Texas |
United States | Sage Investigational Site | Saint Charles | Missouri |
United States | Sage Investigational Site | Washington | District of Columbia |
United States | Sage Investigational Site | Wildomar | California |
Lead Sponsor | Collaborator |
---|---|
Biogen |
United States,
Deligiannidis K, Lasser R, Gunduz-Bruce H, Silber C, Sankoh AJ, Li Si, et al. A Phase 3, Double-Blind, Placebo- Controlled Trial of SAGE-217 in Postpartum Depression: Assessment of Depressive Symptoms Across Multiple Measures. Abstract presented at: Ameri
Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Se — View Citation
Lasser R, Deligiannidis K, Gunduz-Bruce H, Silber C, Sankoh AJ, Li Si, et al. A Phase 3, Double-Blind, Placebo- Controlled Trial of SAGE-217 in Postpartum Depression: Topline Assessment of Secondary Efficacy Measures of Anxiety and Depression. Abstract pr
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 | The 17-item HAM-D is used to rate the severity of depression in participants who are already diagnosed as depressed. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The HAM-D total score was calculated as the sum of the 17 individual item scores and could range from 0 to 52. Higher scores indicated more severe depression. A negative change from Baseline indicates less depression. | Parts A and B: Baseline, Day 15 | |
Secondary | Parts A and B: Change From Baseline in the HAM-D Total Score at Days 3, 8, 21 and 45 | The 17-item HAM-D is used to rate the severity of depression in participants who are already diagnosed as depressed. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The HAM-D total score was calculated as the sum of the 17 individual item scores and could range from 0 to 52. Higher scores indicated more severe depression. A negative change from Baseline indicates less depression. | Part B: Baseline, Days 3, 8, 21 and 45 | |
Secondary | Parts A and B: Percentage of Participants With HAM-D Response | HAM-D Response was defined as having a 50 percent (%) or greater reduction from Baseline in HAM-D total score. The HAM-D total score was calculated as the sum of the 17 individual item scores and could range from 0 to 52. The items on HAM-D included: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early night, middle night, early hours [morning]), work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Higher scores indicated more depression. | Part B: Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Percentage of Participants With HAM-D Remission | HAM-D Remission was defined as a HAM-D total score of less than or equal to (<=)7. The HAM-D total score was calculated as the sum of the 17 individual item scores and could range from 0 to 52. The items on HAM-D included: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early night, middle night, early hours [morning]), work and activities, retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Higher scores indicated more depression. | Part B: Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Change From Baseline in HAM-D Subscales Scores | HAM-D is used to rate the severity of depression in participants who are already diagnosed as depressed. HAM-D subscales: Core subscale (symptoms-depressed mood, feelings of guilt, suicide, work and activities, and retardation ); Anxiety subscale (symptoms-anxiety [psychic and somatic], somatic symptoms [gastrointestinal and general], hypochondriasis, loss of weight); Bech-6 subscale (symptoms-depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general); Meier subscale (symptoms-depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic). Each item was scored in a range of 0 to 2 or 0 to 4, higher scores=greater degree of depression. Subscale scores were calculated as the sum of the individual item scores comprising each subscale. Scores were transformed to a scale of 0 to 100, with higher scores indicated more severe depression. A negative change from Baseline indicates less depression. | Part B: Baseline, Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Change From Baseline in HAM-D Individual Item Scores | The 17-item HAM-D is used to rate the severity of depression in participants who are already diagnosed as depressed. Individual items on the scale were scored in a range of 0 to 2 or 0 to 4. Symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms were scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicated a greater degree of depression. A negative change from Baseline indicates less depression. | Part B: Baseline, Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Change From Baseline in Montgomery and Åsberg Depression Rating Scale (MADRS) Total Score | The MADRS is a 10-item questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item was scored in a range of 0 (no symptoms) to 6 (symptoms of maximum severity). The MADRS total score was calculated as the sum of the 10 individual item scores and could range from 0 to 60. Higher scores indicated more severe depression. A negative change from Baseline indicates less depression. | Part B: Baseline, Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response | The Clinical Global Impression - Improvement (CGI-I) item of the CGI scale uses a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. CGI response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved). The percentage of participants with overall improvement in post-treatment condition, rated by investigator as very much improved (CGI-I score of 1) or much improved (CGI-I score of 2) is reported. | Part B: Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score | The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each of the 14 items was defined by a series of symptoms and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The individual items were scored in a range of 0 (not present) to 4 (very severe). The HAM-A total score was calculated as the sum of the 14 individual item scores and could range from 0 to 56 where a score of <17=mild severity; 18-24= mild to moderate severity and 25-30=moderate to severe severity. A negative change from Baseline indicates less anxiety. | Part B: Baseline, Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Percentage of Participants With MADRS Response | MADRS response was defined as having a 50% or greater reduction from Baseline in MADRS total score. The MADRS is a 10-item questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item was scored in a range of 0 (no symptoms) to 6 (symptoms of maximum severity). The MADRS total score was calculated as the sum of the 10 individual item scores and could range from 0 to 60. Higher scores indicated more depression. | Part B: Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Percentage of Participants With MADRS Remission | MADRS Remission was defined as a MADRS total score of <=10. The MADRS is a 10-item questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item was scored in a range of 0 (no symptoms) to 6 (symptoms of maximum severity). The MADRS total score was calculated as the sum of the 10 individual item scores and could range from 0 to 60. Higher scores indicated more depression. | Part B: Days 3, 8, 15, 21 and 45 | |
Secondary | Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurs after receiving study drug. | Part A: Up to Day 75; Part B: Up to Day 45 | |
Secondary | Part B: Number of Participants With Potentially Clinically Significant Vital Sign Measurements | Vital signs included assessments of supine and standing systolic blood pressure (SBP), supine and standing diastolic blood pressure (DBP), and heart rate. | Part B: From first dose of study drug up to 45 days | |
Secondary | Part B: Number of Participants With Potentially Clinically Significant Laboratory Evaluations | Laboratory tests included tests of Hematology, Chemistry, and Urinalysis. | Part B: From first dose of study drug up to 45 days | |
Secondary | Part B: Change From Baseline in Electrocardiogram (ECG) Parameter Heart Rate | ECG parameters included assessment of the standard 12-lead ECG intervals: QT, QTcF, PR, RR, QRS, and heart rate. Heart rate was measured in terms of beats per minute. Change from Baseline in heart rate at specified time points were reported. | Part B: Baseline, Days 8, 15, and 21 | |
Secondary | Part B: Change From Baseline in ECG Parameters-PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval | ECG parameters included assessment of the standard 12-lead ECG intervals: QT, QTcF, PR, RR, QRS, and heart rate. Change from Baseline in PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval is reported. | Part B: Baseline, Days 8, 15, and 21 | |
Secondary | Part B: Number of Participants With a Response of "Yes" to Any Suicidal Ideation or Suicidal Behaviors Item Using the Columbia Suicide Severity Rating Scale (C-SSRS) | C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for severity of ideation (if present), from 1 to 5, with 5 being the most severe. Number of participants with a response of 'yes' to any suicidal ideation or suicidal behavior item as measured by C-SSRS is reported. | Part B: Up to Day 45 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06348316 -
Early Half Swaddling and Kangaroo Care Practices on Maternal Sleep Quality and Postpartum Depression in Term Babies
|
N/A | |
Completed |
NCT05322161 -
Yoga in the NICU for Parents Study
|
N/A | |
Withdrawn |
NCT03709004 -
Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression
|
N/A | |
Completed |
NCT06305325 -
Coparenting Intervention to Prevent Postpartum Depression
|
N/A | |
Not yet recruiting |
NCT05055674 -
The Effects of Motherly on Postpartum Depression
|
N/A | |
Enrolling by invitation |
NCT02323152 -
PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK
|
N/A | |
Not yet recruiting |
NCT01658098 -
Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez
|
N/A | |
Completed |
NCT00961402 -
The Effect of Exercise on Preventing PostPartum Depression
|
Phase 2 | |
Completed |
NCT01312883 -
Mothers Avoiding Depression Through Empowerment Intervention Trial
|
N/A | |
Completed |
NCT00360204 -
Improving Health Outcomes for New Mothers and Babies
|
Phase 3 | |
Unknown status |
NCT00548743 -
Translating Research Into Practice for Postpartum Depression
|
N/A | |
Completed |
NCT04146025 -
Nurtured in Nature
|
N/A | |
Not yet recruiting |
NCT06442774 -
MamaConecta: Digital Tool for Maternal Mental Health
|
N/A | |
Recruiting |
NCT05137925 -
Mindful Moms: Mechanisms of Mindfulness-based Cognitive Therapy During Pregnancy and Postpartum
|
N/A | |
Not yet recruiting |
NCT05299398 -
Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone
|
Phase 1 | |
Completed |
NCT04925765 -
Virtual Reality Biofeedback for Postpartum Anxiety and Depression
|
N/A | |
Recruiting |
NCT06053515 -
Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication
|
N/A | |
Completed |
NCT04037085 -
Ketamine to Improve Recovery After Cesarean Delivery - Part 1
|
Phase 2 | |
Completed |
NCT05059600 -
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
|
Phase 4 | |
Completed |
NCT06136520 -
The Effect of Baby Massage Training Given to Pregnant Women on Maternal Attachment and Postpartum Depression
|
N/A |